We are live on ! Find out more
ASBPW

Aspire Biopharma Warrant
ASBPW

35 hedge funds and large institutions have $823K invested in Aspire Biopharma Warrant in 2023 Q4 according to their latest regulatory filings, with 0 funds opening new positions, 1 increasing their positions, 2 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

13% more capital invested

Capital invested by funds: $726K → $823K (+$96.6K)

10% less funds holding

Funds holding: 39 → 35 (-4)

50% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 2

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 4

Holders
35
Holders Change
-4
Holders Change %
-10.26%
% of All Funds
0.51%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
1
Reduced
2
Closed
4
Calls
$2.21M
Puts
–
Net Calls
+$2.21M
Net Calls Change
-$143K

Top Buyers

Rank Fund Capital Flow
1
FSI
Flow State Investments
Illinois
+$159

Top Sellers

Rank Fund Capital Flow
1
RCM
Radcliffe Capital Management
Pennsylvania
-$8.12K
2
SRCM
Sage Rock Capital Management
New York
-$8.12K
3
HIM
HGC Investment Management
Ontario, Canada
-$5.07K
4
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$105
5
CS
Clear Street
New York
-$58
Name Holding Trade Value Shares
Change 		Change in
Stake
AC
1
Athos Capital
Hong Kong
$233K – – –
PC
2
Periscope Capital
Ontario, Canada
$87.7K – – –
SCM
3
Saba Capital Management
New York
$63.9K – – –
Adage Capital Partners
4
Adage Capital Partners
Massachusetts
$63K – – –
LA
5
Linden Advisors
New York
$58.5K – – –
HCM
6
Highbridge Capital Management
New York
$45K – – –
AA
7
AQR Arbitrage
Connecticut
$38.9K – – –
SC
8
Sculptor Capital
New York
$32.5K – – –
Verition Fund Management
9
Verition Fund Management
Connecticut
$26K – – –
WAM
10
Wolverine Asset Management
Illinois
$24.1K – – –
Barclays
11
Barclays
United Kingdom
$21K – – –
TCA
12
Taconic Capital Advisors
New York
$18K – – –
D.E. Shaw & Co
13
D.E. Shaw & Co
New York
$12K – – –
SFM
14
Spartan Fund Management
Canada
$11.2K – – –
CCM
15
Context Capital Management
California
$10.5K – – –
Nomura Holdings
16
Nomura Holdings
Japan
$9.07K – – –
PAMP
17
Polar Asset Management Partners
Ontario, Canada
$8.31K – – –
LP
18
LMR Partners
United Kingdom
$7.5K – – –
WA
19
Whitebox Advisors
Minnesota
$7.5K – – –
JP Morgan Chase
20
JP Morgan Chase
New York
$6K – – –
KL
21
KIM LLC
Kansas
$6K – – –
FSI
22
Flow State Investments
Illinois
$6K +$159 +3,832 +4%
CCM
23
CAAS Capital Management
New York
$4.5K – – –
CS
24
Clear Street
New York
$3.19K -$58 -1,400 -3%
ACM
25
Atalaya Capital Management
New York
$3K – – –
1
2

ASBPW Hedge Fund Activity: Q4 2023 in Review

35 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Aspire Biopharma Warrant (ASBPW) for Q4 2023, worth a combined $823K — up 13% from $726K a quarter earlier.

Sellers outnumbered buyers: 4 funds closed out of ASBPW and 0 opened new positions — a net loss of 4 holders — while 2 trimmed existing stakes and 1 added.

The largest buyer was Flow State Investments, adding an estimated $159. The largest seller was Radcliffe Capital Management, exiting entirely with an estimated $8.12K sold.

  • 35 institutional investors held Aspire Biopharma Warrant (ASBPW) as of Q4 2023, down from 39 in Q3 2023.
  • Funds reported $823K of Aspire Biopharma Warrant stock for Q4 2023, up 13% quarter-over-quarter.
  • 0 funds opened new Aspire Biopharma Warrant positions in Q4 2023 and 4 closed out, a net change of -4 holders.
  • The largest Aspire Biopharma Warrant buyer in Q4 2023 was Flow State Investments, an estimated $159 added.
  • The largest Aspire Biopharma Warrant seller in Q4 2023 was Radcliffe Capital Management, an estimated $8.12K sold.

Based on aggregated 13F filings for Q4 2023.